Systematic Review on Customized and Non-customized Device Techniques for the Endovascular Repair of the Aortic Arch

医学 主动脉弓 主动脉修补术 死亡率 外科 动脉瘤 主动脉
作者
Petroula Nana,Κωνσταντίνος Σπανός,Konstantinos Dakis,Athanasios D. Giannoukas,Tilo Kölbel,Stéphan Haulon
出处
期刊:Journal of Endovascular Therapy [SAGE Publishing]
卷期号:31 (4): 505-521 被引量:17
标识
DOI:10.1177/15266028221133701
摘要

Purpose: Open repair remains the standard of care for aortic arch pathologies. However, endovascular management became an attractive alternative for high-risk patients. This study aimed to assess the outcomes of the available endovascular techniques for aortic arch pathology management. Materials and Methods: A search of the English literature (2000–2022) using PubMed, EMBASE, via Ovid, and CENTRAL databases (February 1, 2022) was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Studies reporting on patients with aortic arch pathologies managed with custom-made devices ([CMDs] fenestrated or branched thoracic endovascular aortic repair [F/BTEVAR]) and non-CMDs (parallel graft or surgeon-modified FTEVAR) were eligible. Studies reporting on hybrid or open repair were excluded. Studies’ quality was assessed using the Newcastle-Ottawa Scale. Primary outcomes were technical success, 30 day mortality, and cerebrovascular events (CVEs). Secondary outcomes were re-intervention and mortality during follow-up. Results: Thirty studies (2135 patients) were included. Treatment indications were mainly dissections (652 cases [48.0%, 652/1358]; 90 type A, 506 type B; 364 acute, 163 chronic) and aneurysms (46.9%, 582/1239). Five studies (211 patients) reported on FTEVAR and 10 (388 patients) on BTEVAR. For FTEVAR, technical success rate was 98.3%. Thirty-day mortality was 3.8% and CVE rate was 12.3%. Ten deaths (9.7%) and 19 re-interventions (9%) were recorded during follow-up (24 months). Regarding BTEVAR, technical success rate was 98.7%, and 30 day mortality and CVE rates were 5.4% and 11.0%, respectively. During follow-up (27 months), 64 deaths (18.7%) and 33 re-interventions (9.6%) were recorded. Parallel graft technique was reported in 11 studies (901 patients). Technical success rate was 76.4%. Thirty-day mortality was 3.9% and 32 (4.3%) CVEs were recorded. Thirty-five deaths (4.4%) and 43 re-interventions (5.5%) were reported during follow-up (27 months). Surgeon-modified FTEVAR was described in 5 studies (635 patients). Technical success rate was 91.6%. At 30 days, 15 deaths (2.3%) and 22 CVEs (3.5%) were recorded. During follow-up (19 months), 26 deaths (4.2%) and 21 re-interventions (3.6%) were detected. Conclusions: Endovascular arch repair presented a variable technical success; >95% for F/BTEVAR; ≤90% for non-CMDs. Acceptable 30 day mortality rates were reported. Cerebrovascular event rates ranged up to 10%. These findings, adjacent to the estimated midterm mortality and re-interventions, set the need for further improvement. Clinical Impact Endovascular arch repair gains popularity as a valuable alternative, especially in patients considered unfit for open repair. According the available literature, any endovascular technique, including custom-made or off-the-shelf solutions, may be applied successfully, with acceptable early mortality. However, the perio-operative cerebrovascular event rate is still an issue, indicating the need for further advancements.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
fusucheng完成签到,获得积分10
1秒前
koi完成签到,获得积分20
1秒前
1秒前
聪明摩托完成签到,获得积分10
1秒前
阿纯完成签到,获得积分10
2秒前
3秒前
肱二头肌完成签到,获得积分10
4秒前
5秒前
小王发布了新的文献求助10
5秒前
多情自古空余恨完成签到,获得积分10
6秒前
Qionglin完成签到,获得积分10
8秒前
Bao完成签到 ,获得积分10
9秒前
9秒前
初夏微凉发布了新的文献求助30
9秒前
10秒前
书霂完成签到,获得积分10
10秒前
优秀含羞草完成签到,获得积分10
11秒前
宓沂完成签到,获得积分10
11秒前
vivre223完成签到,获得积分10
11秒前
量子星尘发布了新的文献求助10
12秒前
受伤凌蝶完成签到,获得积分10
13秒前
wenjiejiang完成签到,获得积分10
14秒前
14秒前
zly完成签到 ,获得积分10
15秒前
15秒前
李某人完成签到,获得积分10
15秒前
16秒前
小鱼完成签到,获得积分10
17秒前
小崽总完成签到,获得积分10
17秒前
挽风完成签到,获得积分10
20秒前
20秒前
dxs发布了新的文献求助10
20秒前
苹果沛柔完成签到,获得积分10
21秒前
111完成签到 ,获得积分10
21秒前
Amon完成签到 ,获得积分10
22秒前
结实寄柔完成签到,获得积分10
23秒前
dh完成签到,获得积分0
23秒前
超帅鸭子发布了新的文献求助10
24秒前
苹果沛柔发布了新的文献求助10
25秒前
27秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038388
求助须知:如何正确求助?哪些是违规求助? 3576106
关于积分的说明 11374447
捐赠科研通 3305798
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029